Watch GTHP. Know when insiders buy.
One email the day a filing lands. Free.
GTHP
GUIDED THERAPEUTICS INC
0.25
+0.00 +0.00%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $24.1MP/E —DIV YIELD —FCF YIELD —REV TTM $650K +450.8%NET INCOME −$3.1MNET CASH $678K52W 0.16 – 0.54SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$478K | −$605K | — | -0.01 | −$319K | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $0 | — | — | −$302K | −$500K | — | -0.01 | −$617K | — | — | May 15 |
| Q4 2025 · Dec 31derived | $590K | +58900.0% | 77.6% | −$710K | −$1.2M | — | -0.01 | −$291K | $0 | −$291K | Mar 31 |
| Q3 2025 · Sep 30 | $60K | — | 58.3% | −$485K | −$742K | — | -0.01 | −$277K | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $117K | — | 67.5% | −$763K | −$811K | — | -0.01 | −$169K | — | — | Aug 13 |
| Q1 2025 · Mar 31 | $0 | −100.0% | — | −$414K | −$427K | — | -0.01 | −$331K | — | — | May 15 |
| Q4 2024 · Dec 31derived | $1K | −96.9% | -200.0% | −$534K | −$652K | — | -0.02 | −$332K | $0 | −$332K | Mar 31 |
| Q3 2024 · Sep 30 | $0 | — | — | −$561K | −$654K | — | -0.01 | −$473K | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $0 | — | — | −$655K | −$709K | — | -0.01 | −$214K | — | — | Aug 14 |
| Q1 2024 · Mar 31 | $6K | — | 66.7% | −$359K | −$402 | — | -0.01 | −$100K | — | — | May 15 |
| Q4 2023 · Dec 31derived | $32K | — | 50.0% | −$485K | −$386K | — | 0.00 | −$336K | $0 | −$336K | Mar 31 |
| Q3 2023 · Sep 30 | $0 | — | — | −$623K | −$677K | — | -0.01 | −$473K | $0 | −$473K | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $767K | 74.4% | −$2.4M | −$3.2M | -416.7% | -0.04 | −$1.1M | $2K | −$1.1M | — | — |
| FY2024 · to Dec 31 | $7K | 28.6% | −$2.1M | −$2.4M | -34528.6% | -0.05 | −$1.1M | $0 | −$1.1M | — | — |
| FY2023 · to Dec 31 | $98K | 36.7% | −$3.5M | −$3.5M | -3560.2% | -0.07 | −$1.7M | $0 | −$1.7M | — | — |
| FY2022 · to Dec 31 | $13K | -523.1% | −$3.3M | −$4.3M | -33392.3% | -0.15 | −$1.5M | $31K | −$1.5M | — | — |
| FY2021 · to Dec 31 | $81K | 24.7% | −$2.4M | −$2.1M | -2555.6% | -0.18 | −$1.6M | $14K | −$1.6M | — | — |
| FY2020 · to Dec 31 | $102K | 140.2% | −$1.1M | −$279K | -273.5% | -0.04 | −$1.9M | $1K | −$1.9M | — | — |
Every number comes from GUIDED THERAPEUTICS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.